AlphaStocks
4.7
Weak

Roivant Sciences Ltd. (ROIV)

Health Care / Biotechnology

S&P MidCap 400

$27.83

Below average on several measures. Research carefully.

Weak

Score based on 3 of 5 models — moderate confidence

#660out of 1127 in Health Care

Is Roivant Sciences Ltd. a Good Investment in 2026?

Roivant Sciences Ltd. (ROIV) scores 4.7 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model is the most favorable, rating Roivant Sciences Ltd. as Caution. However, the Graham model rates it Caution. Roivant Sciences Ltd. ranks #660 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-3.5Market Cap20B

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Caution

2/9

Buffett

Caution

Business quality & competitive moat

Graham

Caution

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is Roivant Sciences Ltd. (ROIV) a good investment?
Based on AlphaStocks' composite analysis, Roivant Sciences Ltd. (ROIV) scores 4.7 out of 10, earning a Weak rating. This score is below average, suggesting caution. Currently unprofitable — fair value estimate not available.
What is Roivant Sciences Ltd.'s Piotroski F-Score?
Roivant Sciences Ltd.'s Piotroski F-Score status is Caution. The raw score is 2/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is ROIV overvalued or undervalued?
A precise fair value estimate is not available for ROIV. Currently unprofitable — fair value estimate not available.
How does ROIV compare to other Health Care stocks?
Roivant Sciences Ltd. ranks #660 out of 1127 stocks in the Health Care sector, placing it in the top 59% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about ROIV?
AlphaStocks evaluates ROIV using five proven investment models. Piotroski: Caution; Buffett: Caution; Graham: Caution. These models are combined into a single composite score of 4.7/10.

Similar Stocks

PARRFTIAZN

Compare ROIV with

ROIV vs PARRROIV vs FTIROIV vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer